Related Experiment Video

Updated: Jul 15, 2026

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a single-dose hyperglycaemic

A Farret1, H Chevassus, B Roux

  • 1CHU Montpellier, Centre d'Investigation Clinique, Montpellier, France.

Diabetologia
|May 9, 2007
PubMed
Abstract

Insights

A single dose of rosiglitazone rapidly improved insulin clearance and insulin sensitivity in healthy volunteers. This study found no direct effect on insulin secretion, suggesting complex mechanisms for rosiglitazone

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Research

Background:

  • Thiazolidinediones are known to improve insulin sensitivity and modulate beta-cell function in type 2 diabetes.
  • Confounding factors in diabetic patients complicate the assessment of specific drug effects on beta-cell function and insulin clearance.
  • Understanding the acute effects of rosiglitazone in healthy individuals provides a baseline for its pharmacological actions.

Purpose of the Study:

  • To investigate the acute effects of rosiglitazone on beta-cell function.
  • To assess the impact of rosiglitazone on insulin sensitivity.
  • To determine if rosiglitazone influences insulin clearance in healthy volunteers using the hyperglycaemic clamp technique.

Main Methods:

  • A randomized, double-blind, crossover study involving twelve healthy male volunteers.
  • Administration of a single oral dose of rosiglitazone (8 mg) or placebo.
  • Utilized the hyperglycaemic clamp technique (10 mmol/l for 2 hours) to measure metabolic responses.

Main Results:

  • Rosiglitazone significantly decreased the second phase of insulin response (p < 0.05) without altering the first phase or serum C-peptide levels.
  • A significant increase in insulin clearance was observed with rosiglitazone treatment (p < 0.05).
  • Rosiglitazone treatment significantly enhanced the insulin sensitivity index (p < 0.01).

Conclusions:

  • A single dose of rosiglitazone acutely increases insulin clearance and the insulin sensitivity index in healthy individuals.
  • The study found no direct acute effect of rosiglitazone on insulin secretion in this population.
  • Further research is needed to elucidate the precise mechanisms underlying these observed pharmacological effects.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...